192 related articles for article (PubMed ID: 21962388)
41. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
[TBL] [Abstract][Full Text] [Related]
42. Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study.
Ajeganova S; Fiskesund R; de Faire U; Hafström I; Frostegård J
Clin Exp Rheumatol; 2011; 29(6):942-50. PubMed ID: 22153361
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
Tak PP; Rigby WF; Rubbert-Roth A; Peterfy CG; van Vollenhoven RF; Stohl W; Hessey E; Chen A; Tyrrell H; Shaw TM;
Ann Rheum Dis; 2011 Jan; 70(1):39-46. PubMed ID: 20937671
[TBL] [Abstract][Full Text] [Related]
44. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
[TBL] [Abstract][Full Text] [Related]
45. The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis.
Favalli EG; Pregnolato F; Biggioggero M; Meroni PL
Semin Arthritis Rheum; 2014 Jun; 43(6):730-7. PubMed ID: 24332807
[TBL] [Abstract][Full Text] [Related]
46. ACP Journal Club. Review: In rheumatoid arthritis, adding rituximab to methotrexate improves clinical outcomes.
Schattner A
Ann Intern Med; 2015 Jun; 162(12):JC9. PubMed ID: 26075786
[No Abstract] [Full Text] [Related]
47. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
48. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
[TBL] [Abstract][Full Text] [Related]
49. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice.
Manders SH; Kievit W; Adang E; Jansen TJ; Stolk JN; Visser H; Schilder AM; Vonkeman HE; van de Laar MA; van Riel PL
Ann Rheum Dis; 2015 Mar; 74(3):e24. PubMed ID: 25480886
[No Abstract] [Full Text] [Related]
51. A decade of data discloses the window is still not clear.
Cohen M
J Rheumatol; 2014 Jan; 41(1):1-2. PubMed ID: 24382923
[No Abstract] [Full Text] [Related]
52. Adalimumab for rheumatoid arthritis?
Ebell M; Kripke C
Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667
[No Abstract] [Full Text] [Related]
53. Biological therapy for rheumatoid arthritis: where are we now?
Horton SC; Emery P
Br J Hosp Med (Lond); 2012 Jan; 73(1):12-8. PubMed ID: 22241404
[TBL] [Abstract][Full Text] [Related]
54. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
55. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis.
Papagoras C; Voulgari PV; Drosos AA
Autoimmun Rev; 2010 Jun; 9(8):574-82. PubMed ID: 20433955
[TBL] [Abstract][Full Text] [Related]
56. Rheumatoid arthritis: more aggressive approach improves outlook.
Weinblatt ME
Cleve Clin J Med; 2004 May; 71(5):409-13. PubMed ID: 15195775
[TBL] [Abstract][Full Text] [Related]
57. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
[TBL] [Abstract][Full Text] [Related]
58. [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model].
Brodszky V
Orv Hetil; 2011 Jun; 152(23):919-28. PubMed ID: 21592952
[TBL] [Abstract][Full Text] [Related]
59. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
60. Decrease of CD68 and MMP-3 expression in synovium by treatment of adalimumab for rheumatoid arthritis.
Kanbe K; Chiba J; Nakamura A
Int J Rheum Dis; 2011 Aug; 14(3):261-6. PubMed ID: 21816022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
